18 天前 - … of oral antiviral therapy including nirmatrelvir plus ritonavir and molnupiravir in
managing COVID-19 … agents in the management of COVID-19 among patients with lung cancer. …

36 天前 - … Molnupiravir (MOV) is an oral antiviral for the treatment of individuals with mild-to-moderate
COVID-19 and at … benefits of molnupiravir in non-hospitalized adults with COVID-19. …

63 天前 - … in non-hospitalized, adult COVID-19 patients prescribed MOV in … Molnupiravir (MOV)
is an orally bioavailable … only antiviral drug available for COVID-19 treatment in the Czech …

76 天前 - … or molnupiravir and the outcomes of non-hospitalized high… risk patients with COVID-19
received oral antiviral treatment … oral antiviral treatments among high-risk individuals with …

85 天前 - … Both combinations of nirmatrelvir plus ritonavir (NMV-r) and molnupiravir (MOV) have
… and death in non-hospitalized adult patients with mild-to-moderate COVID-19 who are at …

110 天前 - … Oral VV116 versus placebo in patients with mild-to-moderate … Molnupiravir plus
usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk …

131 天前 - … Molnupiravir is an oral prodrug of the broadly active, antiviral … of nonhospitalized
patients with COVID-19 (MOVe-OUT), 5 days of treatment with 800 mg molnupiravir Q12H …

132 天前 - … with COVID-19. Twenty-two studies representing 17,525 patients reported both
treatment … The treatment effect (relative risk) on hospitalization or death amongst outpatients with …

138 天前 - … plus ritonavir and molnupiravir, in treating COVID-19 in patients with nonalcoholic
fatty … of novel oral antiviral agents is effective for treating COVID-19 in patients with MAFLD. …

194 天前 - … three countries for the treatment of mild COVID-19. The aim of … by 50% in non-hospitalized
COVID-19 patients. Conclusion … Molnupiravir is one of the oral antiviral drugs under …